EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Vergleichsstudie

Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype

Nuchanun Kessakorn iD, Itsaraet Gosriwatana, Nuttarak Sasipong, Chonlatis Srichumpuang iD, Chatphatai Moonla iD, Darintr Sosothikul iD

Haemophilia · 2025

DOI: 10.1111/hae.15146 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Haemophilia, 2025. Verfasst von Nuchanun Kessakorn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memoria…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII, Hemophilia A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous emicizumab, a factor VIII (FVIII)‐mimicking bispecific monoclonal antibody, can effectively prevent bleeds in haemophilia A (HA) patients with/without inhibitors; however, its standard‐dose regimens are financially burdensome. Low‐dose emicizumab prophylaxis may alternatively be applied to noninhibitor HA patients in resource‐limited settings.

Methods

During 2023, Thai patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype (historical annualized bleeding rate [ABR] >5 bleeds/year before regular FVIII prophylaxis) who received low‐/intermediate‐dose FVIII secondary prophylaxis ≥8 months were enrolled. After the 4‐day washout period, low‐dose emicizumab prophylaxis (2.0–2.5 mg/kg every fortnight for two loading doses, then every 4 weeks) was implemented for 8 months. Pre‐/post‐emicizumab ABR, annualized joint bleeding rates (AJBR), haemophilia joint health scores (HJHS) and haemophilia‐specific quality‐of‐life (QoL) scores were analysed. Emicizumab plasma levels on modified one‐stage FVIII assays were also monitored.

Results

In 15 subjects, ABR (median of differences, −2 bleeds/year; interquartile range, −3 to 0; p = 0.002), but not AJBR ( p = 0.07), were reduced after switching to low‐dose emicizumab prophylaxis, although the pre‐dose emicizumab plasma levels at the steady state, achieved since week 12, were modest (median monthly level, 8.4 µg/mL; interquartile range, 4.3–10.4). Concurrently, HJHS ( p = 0.008) and QoL score ( p < 0.001) were decreased, and 46.7% had zero bleeds while receiving low‐dose emicizumab.

Conclusions

Low‐dose emicizumab, compared to low‐/intermediate‐dose FVIII secondary prophylaxis, meaningfully improves bleeding prevention, joint health and QoL in patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype. This regimen potentially helps address previously unmet needs in HA care among low‐to‐middle‐income countries. Trial Registration ClinicalTrials.gov identifier NCT06155955.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedFactor VIIIHemophilia AHemorrhageSecondary PreventionAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultPhenotypeQuality of Life

Stichwörter der Autor:innen

emicizumabfactor VIIIhaemophilia A

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, HumanizedemicizumabFactor VIII

Autor:innen und Institutionen

  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Chulalongkorn University International Medical Program (CU-MEDi), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Division of General Internal Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Nuchanun Kessakorn, Chonlatis Srichumpuang, Chatphatai Moonla, Darintr Sosothikul

Zitieren

APA

Kessakorn, N., Gosriwatana, I., Sasipong, N., Srichumpuang, C., Moonla, C., & Sosothikul, D. (2025). Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype. Haemophilia. https://doi.org/10.1111/hae.15146

Vancouver

Kessakorn N, Gosriwatana I, Sasipong N, Srichumpuang C, Moonla C, Sosothikul D. Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype. Haemophilia. 2025. doi:10.1111/hae.15146

BibTeX
@article{Kessakorn2025,
  author = {Kessakorn, Nuchanun and Gosriwatana, Itsaraet and Sasipong, Nuttarak and Srichumpuang, Chonlatis and Moonla, Chatphatai and Sosothikul, Darintr},
  title = {Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.15146}
}
Kostenlos starten →